413 related articles for article (PubMed ID: 29409576)
41. The Opioid Crisis and the Physician's Role in Contributing to its Resolution: Step One--Prevention of Overdoses.
Wolfe S; Bouffard DL; Modesto-Lowe V
Conn Med; 2016; 80(6):325-34. PubMed ID: 27509638
[TBL] [Abstract][Full Text] [Related]
42. Distribution of naloxone for overdose prevention to chronic pain patients.
Coe MA; Walsh SL
Prev Med; 2015 Nov; 80():41-3. PubMed ID: 26024850
[TBL] [Abstract][Full Text] [Related]
43. Co-prescription of naloxone as a Universal Precautions model for patients on chronic opioid therapy-Observational study.
Takeda MY; Katzman JG; Dole E; Bennett MH; Alchbli A; Duhigg D; Yonas H
Subst Abus; 2016; 37(4):591-596. PubMed ID: 27093555
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of knowledge and confidence following opioid overdose prevention training: A comparison of types of training participants and naloxone administration methods.
Ashrafioun L; Gamble S; Herrmann M; Baciewicz G
Subst Abus; 2016; 37(1):76-81. PubMed ID: 26514071
[TBL] [Abstract][Full Text] [Related]
45. Clinical pharmacist involvement in expanding naloxone distribution in a veteran population.
McQuillan A
Am J Health Syst Pharm; 2022 Mar; 79(6):472-476. PubMed ID: 34755851
[TBL] [Abstract][Full Text] [Related]
46. Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management.
Dunn KE; Barrett FS; Bigelow GE
Addict Behav; 2018 Nov; 86():56-60. PubMed ID: 29625751
[TBL] [Abstract][Full Text] [Related]
47. How competent are people who use opioids at responding to overdoses? Qualitative analyses of actions and decisions taken during overdose emergencies.
Neale J; Brown C; Campbell ANC; Jones JD; Metz VE; Strang J; Comer SD
Addiction; 2019 Apr; 114(4):708-718. PubMed ID: 30476356
[TBL] [Abstract][Full Text] [Related]
48. Expanding the role of clinical pharmacists on interdisciplinary primary care teams for chronic pain and opioid management.
Giannitrapani KF; Glassman PA; Vang D; McKelvey JC; Thomas Day R; Dobscha SK; Lorenz KA
BMC Fam Pract; 2018 Jul; 19(1):107. PubMed ID: 29970008
[TBL] [Abstract][Full Text] [Related]
49. The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group.
Skelton JB; Dharbhamalla V
J Manag Care Spec Pharm; 2022 Jan; 28(1):100-106. PubMed ID: 34949114
[TBL] [Abstract][Full Text] [Related]
50. Emergency department physicians' and pharmacists' perspectives on take-home naloxone.
Holland TJ; Penm J; Dinh M; Aran S; Chaar B
Drug Alcohol Rev; 2019 Feb; 38(2):169-176. PubMed ID: 30697852
[TBL] [Abstract][Full Text] [Related]
51. Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.
Olsen A; Lawton B; Dwyer R; Taing MW; Chun KLJ; Hollingworth S; Nielsen S
Int J Drug Policy; 2019 Jul; 69():46-52. PubMed ID: 31078908
[TBL] [Abstract][Full Text] [Related]
52. Development and process evaluation of an educational intervention for overdose prevention and naloxone distribution by general practice trainees.
Klimas J; Egan M; Tobin H; Coleman N; Bury G
BMC Med Educ; 2015 Nov; 15():206. PubMed ID: 26590066
[TBL] [Abstract][Full Text] [Related]
53. Attitudes Toward Naloxone Prescribing in Clinical Settings: A Qualitative Study of Patients Prescribed High Dose Opioids for Chronic Non-Cancer Pain.
Mueller SR; Koester S; Glanz JM; Gardner EM; Binswanger IA
J Gen Intern Med; 2017 Mar; 32(3):277-283. PubMed ID: 27798775
[TBL] [Abstract][Full Text] [Related]
54. Naloxone's basic benefit. Why the overdose-reversal drug is worth expanding beyond just ALS providers.
Furlano E
EMS World; 2014 Oct; 43(10):28-30, 32-4. PubMed ID: 25812292
[No Abstract] [Full Text] [Related]
55. Acceptability and feasibility of naloxone prescribing in primary care settings: A systematic review.
Behar E; Bagnulo R; Coffin PO
Prev Med; 2018 Sep; 114():79-87. PubMed ID: 29908763
[TBL] [Abstract][Full Text] [Related]
56. Implementing take-home naloxone in an urban community pharmacy.
Akers JL; Hansen RN; Oftebro RD
J Am Pharm Assoc (2003); 2017; 57(2S):S161-S167. PubMed ID: 28202384
[TBL] [Abstract][Full Text] [Related]
57. Opioid education and nasal naloxone rescue kits in the emergency department.
Dwyer K; Walley AY; Langlois BK; Mitchell PM; Nelson KP; Cromwell J; Bernstein E
West J Emerg Med; 2015 May; 16(3):381-4. PubMed ID: 25987910
[TBL] [Abstract][Full Text] [Related]
58. Public attitudes and beliefs about Virginia community pharmacists dispensing and administering naloxone.
Haggerty LC; Gatewood SS; Goode JKR
J Am Pharm Assoc (2003); 2018; 58(4S):S73-S77.e1. PubMed ID: 30006189
[TBL] [Abstract][Full Text] [Related]
59. Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose.
Abouk R; Pacula RL; Powell D
JAMA Intern Med; 2019 Jun; 179(6):805-811. PubMed ID: 31058922
[TBL] [Abstract][Full Text] [Related]
60. An increase in per-patient naloxone requirements in an opioid epidemic.
Birmingham LE; Nielson JA
Am J Emerg Med; 2017 Dec; 35(12):1958-1959. PubMed ID: 28633907
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
